The objectives of this study were to determine whether or not the probiotic LactobaciUus GG 
bifidobacteria may be delayed.3 Preterm infants are predisposed to infection from bacteria encountered in the hospital environment. The bacteria that most frequently cause nosocomial infections of infants in intensive care are coagulase negative staphylococci and enterobacteriaceae. The bowel provides the major reservoir both for enterobacteriaceae,4 which may also contribute to the pathogenesis of neonatal necrotising enterocolitis,5 6 and in the first few weeks of life coagulase negative staphylococci.
A probiotic can be defined as 'a live microbial feed supplement which beneficially affect the host animals by improving intestinal microbial balance'.7 It has been suggested that induced colonisation of preterm infants with a probiotic may produce bacteriological, metabolic, and clinical benefits for these infants. 8 In human adult and animal studies lactobacilli have been among the commonest organisms used in probiotic studies.9 10 In addition to preventing bowel colonisation by other microbes by competing for binding sites and substrates in the bowel, lactobacilli can produce a wide range of antibacterial substances such as organic acids, bacteriocins, microcins, reuterin, volatile fatty acids, hydrogen peroxide, and hydrogen ions.11-13 Lacto- bacillus GG is a strain of Lactobacillus caseii that can colonise the bowel of adults and has been used in the treatment of pseudomembranous colitis and traveller's diarrhoea.14 15 Although Lactobacillus GG has not been reported to have been given to newborn infants, it has been used to treat relatively young infants suffering from acute gastroenteritis with no reported side effects. 16 The objectives of this study were (i) to determine whether or not the probiotic Lactobacillus GG can colonise the immature bowel of premature infants and (ii) if so, does colonisation result in a reduction of the size of the bowel reservoir of nosocomial pathogens such as enterobacteriaceae, enterococci, yeasts or staphylococci, and (iii) does colonisation with Lactobacillus GG have any effect on clinical progress and outcome.
Patients and methods
In a preliminary investigation we determined the tolerability of feed supplementation with Lactobacillus GG. Three infants with gestational ages 25, 31, and 32 weeks and birth weights 860, 1380, and 2130 g were recruited after informed parental consent had been obtained. This part of the study was not blinded in order to allow the opportunity for evaluation of changes in clinical condition. Lactobacillus GG was supplied as a freeze dried powder containing 1011 colony forming units (cfu)/g dry weight and was obtained from Valio Finnish Co-operative Dairies Association, Finland. Each day a stock solution of Lactobacillus GG was prepared using a sterile technique by suspension of freeze dried powder in sterile distilled water to give 109 cfu/ml. The suspension was stored at 4°C for up to 12 hours. The suspension was then diluted in milk to give the required concentration of bacteria in feeds. The first dose was usually given with the initiation of milk feeds. All of these infants received parenteral antibiotics. The study was approved by the local ethics committee.
The first infant studied received 104 cfu Lactobacillus GG in a single feed for five days. This resulted in bowel colonisation with counts ranging from 104 cfulg dry weight of stool in the first week after administration to 106 cfu/g dry weight of stool five weeks later with a maximum count 108 cfu/g dry weight of stool two weeks after receiving the first dose of Lactobacillus GG. The next infant received 106 as a single dose for five days and in this infant colonisation was not so consistent -indeed Lactobacillus GG was isolated on only one occasion, at a count of 1010 cfu/g dry weight of stool one week after the start of feed supplementation. The third infant received 106 twice daily for 14 days. Lactobacillus GG was isolated again on only one occasion at a count of 109 cfu/g dry weight of stool two weeks after the start of feed supplementation. Lactobacillus GG feed supplementation was well tolerated and there appeared to be no detrimental clinical effects.
Subsequent to these preliminary studies a randomised, double blind study of the effects of Lactobacillus GG in preterm infants was undertaken. Twenty preterm infants with a gestational age of 33 weeks or less who were admitted to the neonatal unit of the Princess Anne Hospital, Southampton between 1 September 1991 and 31 January 1992 were studied. After informed parental consent had been obtained the infants were randomised to receive either milk feeds with Lactobacillus GG (group A) or unsupplemented milk feeds (group B). The infants received a variety of milks, including expressed breast milk, formula, or preterm formula. In some instances a mixture of milks was given, according to the parent's choice and the infant's clinical requirements. The median gestational age and birth weight in group A were 30 5 weeks (range 26-33) and 1445 g (range 800-2560) and in group B were 30 weeks (range 24-33) and 1500 g (range 830-2150). Six of 10 in group A and two of 10 in group B were born by caesarean section. Two in each group were born after prolonged rupture of membranes (>24 hours).
Those infants randomised to receive Lactobacillus GG were given 108 cfu twice a day in milk from the initiation of milk feeds for 14 days. All the infants were studied for their full stay in the neonatal unit. Every infant was examined daily by a physician who was actively involved in the care of the infants on the neonatal unit but who was not aware of the study randomisation schedule. The following clinical details were recorded daily: general well being, any signs of abdominal distension, vomiting or regurgitation, feed intolerance, the incidence of perineal rash, the frequency and consistency of stools, the number of suppositories used, and the fluid intake. The exact type and amount of fluid was recorded and the total energy intake was then calculated. The weight of each infant was recorded three times weekly.
Other clinical variables evaluated included any clinical or laboratory evidence of sepsis, antibiotic treatment or any other concomitant medication, and oxygen and ventilatory requirements; the duration of hospital stay was also calculated for each group.
Samples of milk supplemented with Lactobacillus GG were collected daily for culture on selective and non-selective media to ensure that they were not contaminated with other bacteria or with yeasts. Faecal samples were collected each day and sent in a GasPak Pouch (BBL Microbiology Systems, PO Box 243, Cockeysville, MD 21030, USA) to the microbiology laboratory for quantitative studies. Samples were not collected from infants after discharge from hospital. Samples were labelled with the names of infants but the randomisation group was not given to the laboratory staff carrying out the quantitative bacteriology. Weighed faecal samples were stored at -70°C in glycerol citrate broths usually within 24 hours of collection. The maximum time that elapsed before samples were frozen was 72 hours. The dry weight for a known wet weight was determined for each sample that was stored. Quantitative bacteriology was performed within four months of sample storage using the methods that have been previously described.4 Samples selected for quantitative bacteriology were those collected on the day of oral feeding and seven, 14, 21, 28, and 35 days after the introduction of oral feeds. If samples were not available for the exact day, then the next sample passed was selected, providing it was within the next 72 hours. The day on which enterobacteriaceae were first isolated was determined by inoculation of an aliquot from all of the stored samples from each infant on to MacConkey agar. Identification of isolates was with standard laboratory methods.'7 Members of the family enterobacteriaceae were speciated using the Mast ID system (Mast Laboratories, Bootle). Isolates described as Lactobacillus GG were defined as Gram positive bacilli, catalase negative, forming large white colonies on Rogosa's agar in air after 48 hours incubation at 37°C, hydrolysing aesculin and fermenting mannitol, sorbitol, amygdalin, glucose and dulcitol, and which did not ferment lactose, maltose, xylose, rhamnose, sucrose, melibiose, or inositol.
The Mann-Whitney U test was used to compare any differences in the numbers (logl0 Weeks after feeding o Group with Lactobacillus GG supplementation Figure 3 Quantitative changes in enterococci and age afterfeeding. Intravenous antibiotic treatment was administered to eight of the 10 infants who were given feed supplementation with Lactobacillus GG and to seven of the infants in group B. Antibiotic treatment in the first week of life did not seem to affect colonisation with Lactobacillus GG. However, three of the infants in group A did receive intravenous flucloxacillin and netilimicin after the first week of life and in each case there was a more than four times loglo fall in the numbers of Lactobacillus GG in the seven days after the start of antibiotic treatment. The only infant who showed no evidence of colonisation with Lactobacillus GG had received intravenous cefotaxime from soon after birth and was then treated continuously with a variety of parenteral antibiotics until the 14th day of life. There were no cases of proved sepsis in either of the two groups at any time, although one of the infants in each group was found to have perineal candida infection that required treatment with topical and oral nystatin. The possible side effects of oral feeding with Lactobacillus GG include infection and adverse metabolic effects. There were no episodes of infection attributable to Lactobacillus GG in the small number of infants included in this study. L caseii does not ferment lactose to D-lactate23 so that D-lactate acidosis is an unlikely complication. The metabolic consequences of oral feeding with Lactobaci1lus GG are addressed in the companion paper in this issue. 24 The absence of evidence of colonisation with Lactobacillus GG in one infant, the eradication of colonisation in another, and a considerable fall in the level of colonisation of a third infant were associated with the use of flucloxacillin and netilmicin after the first week of life, suggesting that intravenous flucloxacillin and netilimicin may have a profound influence on bowel colonisation with Lactobacillus GG in preterm infants. The transient colonisation of one infant not given feed supplementation with Lactobacillus GG may have arisen as a result of cross colonisation from a twin given feed supplementation with Lactobacillus GG or as a result of accidental feeding with supplemented feed.
The results of this study do not preclude the possibility that Lactobacillus GG colonisation modified intestinal substrate metabolism9 or the pattern of small bowel colonisation. There is evidence from animal and chemostat models that colonisation with lactobacilli reduces E coli colonisation of the small intestine more effectively than the large intestine.25 This study has clearly shown that Lactobacillus GG can colonise the bowel of premature infants. However bowel colonisation with Lactobacillus GG did not reduce the large bowel reservoir of nosocomial pathogens. The findings of this study suggest that feed supplementation with Lactobacillus GG has little or no clinical or bacteriological benefit for premature infants.
We would like to thank the Wessex region for funding this study, Wessex Medical Trust for paying the salary of S L Smith and Scientific Hospital Supplies for arranging the supply of Lactobacillus GG. 
